TC
BBIO icon

Truvestments Capital’s BridgeBio Pharma BBIO Stock Holding History

Truvestments Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.5K Buy
1,229
+74
+6% +$5.18K 0.01% 420
2026
Q1 		$85.8K Hold
1,155
– – 0.02% 406
2025
Q4 		$88.3K Buy
1,155
+612
+113% +$40.2K 0.02% 358
2025
Q3 		$28.2K Buy
543
+83
+18% +$4.05K 0.01% 533
2025
Q2 		$19.9K Buy
+460
New +$16.7K ﹤0.01% 536

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Truvestments Capital's BBIO Position: Q2 2026 in Review

Truvestments Capital increased its BridgeBio Pharma (BBIO) stake by 6.4% in Q2 2026, buying an estimated $5.18K and bringing the position to 1,229 shares worth $91.5K. The position accounts for 0.01% of the portfolio, ranked #420.

Truvestments Capital first reported a position in BBIO in Q2 2025 and has held it in 5 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Truvestments Capital held 1,229 shares of BridgeBio Pharma worth $91.5K as of Q2 2026.
  • Truvestments Capital bought 74 BridgeBio Pharma shares in Q2 2026, an estimated $5.18K.
  • BridgeBio Pharma made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #420 holding.
  • Truvestments Capital first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 5 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.